Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Sector
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Net Margin | - | - | - | - | - | - | - | - | -37K% | - |
ROA | -26% | -31% | -60% | -27% | -60% | -34% | -44% | -60% | -57% | -52% |
ROE | -27% | -61% | -63% | -27% | -66% | -40% | -55% | -79% | -76% | -66% |
The average Net Margin over the past 5 years is -37.35K%.
The trend of Net Margin over the past 5 years is -.
The average ROA over the past 5 years is -46.96%.
The trend of ROA over the past 5 years is -4.63%.
The average ROE over the past 5 years is -57.06%.
The trend of ROE over the past 5 years is -8.63%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | - | - | - | - | - | - | - | - | - | - |
Debt Equity | - | - | - | - | - | - | - | - | - | - |
MIN | ||||||||||
Graham Stability | - | - | - | - | - | - | - | - | - | - |
The Debt/FCF trailing twelve month is -.
The trend of Debt/FCF over the past 5 years is -.
Graham’s Stability measure stands at -.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
---|---|---|---|---|---|
Revenue | - | - | - | - | - |
Net Income | - | - | - | - | - |
Stockholders Equity | 20% | 4.6% | -3.8% | 17% | -13% |
FCF | - | - | - | - | - |
The Revenue CAGR over the past 5 years is -.
The trend of Revenue growth rate over the past 5 years is -.
The Earnings CAGR over the past 5 years is +29.15%.
The trend of Earnings growth rate over the past 5 years is -.
The Equity CAGR over the past 5 years is +4.63%.
The trend of Equity growth rate over the past 5 years is -13.1%.
The FCF CAGR over the past 5 years is +30.25%.
The trend of FCF growth rate over the past 5 years is -.